Novo Nordisk Presentations & Investor Relations material

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of today's biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible. Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done. This page isn't intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk's office in the country you live in: For other customer complaints please contact us here: keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industries. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other Linkedin users. Learn more about our community guidelines here

novonordisk.com

Novo Nordisk presentations

Full Year 2023 Investor Presentation image

Full Year 2023 Investor Presentation

Novo Nordisk logo
Novo Nordisk
Novo Nordisk Annual Report 2021 image

Novo Nordisk Annual Report 2021

Novo Nordisk logo
Novo Nordisk
Investor Presentation - First Six Months of 2021 image

Investor Presentation - First Six Months of 2021

Novo Nordisk logo
Novo Nordisk
CMD22 Capital Markets Day image

CMD22 Capital Markets Day

Novo Nordisk logo
Novo Nordisk
Investor Presentation Q1 2023 image

Investor Presentation Q1 2023

Novo Nordisk logo
Novo Nordisk
First Quarter 2018 Investor Presentation image

First Quarter 2018 Investor Presentation

Novo Nordisk logo
Novo Nordisk
Investor Presentation Q1-Q3 2020 image

Investor Presentation Q1-Q3 2020

Novo Nordisk logo
Novo Nordisk
Investor Presentation - First Nine Months of 2016 image

Investor Presentation - First Nine Months of 2016

Novo Nordisk logo
Novo Nordisk
Investor Presentation First Nine Months of 2023 image

Investor Presentation First Nine Months of 2023

Novo Nordisk logo
Novo Nordisk
Capital Markets Day: Commercial Execution and Innovation in Obesity Care image

Capital Markets Day: Commercial Execution and Innovation in Obesity Care

Novo Nordisk logo
Novo Nordisk
Investor Presentation Q1 2022 image

Investor Presentation Q1 2022

Novo Nordisk logo
Novo Nordisk
Investor Presentation: First Nine Months of 2020 image

Investor Presentation: First Nine Months of 2020

Novo Nordisk logo
Novo Nordisk
Investor Presentation H1 2023 image

Investor Presentation H1 2023

Novo Nordisk logo
Novo Nordisk
Investor Presentation Full Year 2021 image

Investor Presentation Full Year 2021

Novo Nordisk logo
Novo Nordisk
Investor Presentation Full Year 2017 image

Investor Presentation Full Year 2017

Novo Nordisk logo
Novo Nordisk
Investor Presentation image

Investor Presentation

Novo Nordisk logo
Novo Nordisk
Novo Nordisk Investor Presentation - First Nine Months of 2016 image

Novo Nordisk Investor Presentation - First Nine Months of 2016

Novo Nordisk logo
Novo Nordisk
Investor Presentation Q1 2018 image

Investor Presentation Q1 2018

Novo Nordisk logo
Novo Nordisk
Investor Presentation First Nine Months of 2022 image

Investor Presentation First Nine Months of 2022

Novo Nordisk logo
Novo Nordisk